Paranta Biosciences Pty Limited
Paranta Biosciences is a clinical-stage biopharmaceutical company developing potentially transformative first-in-class biotherapeutics based on PB01, a unique form of recombinant human follistatin, targeting inflammatory, fibrotic and metabolic diseases with significant unmet need.
The Company is progressing three development programs:
(i) Respiratory – Inhalation of PB01 for treating cystic fibrosis (CF) lung disease
(ii) Nephrology – Injection of PB01 for treating chronic kidney disease
(iii) Oncology – Injection/infusion of PB01 for treating cancer
Recruited the Company’s CEO (Ross Barrow).
Advised on corporate development strategy.
Conducted an initial capital raising of $7 million through an Information Memorandum at $1.00 per share and several subsequent capital raisings, raising a total of $17m.
Provided liaison with a major Australian research institute for applications of Paranta’s technology in oncology.
To learn more about Paranta Biosciences Pty. Limited, visit their web-site
Previous client |